Company intelligence / Profile preview
Polaris Pharmaceuticals
San Diego, California, United Statespolarispharma.com ↗
- Ownership
- Private
- Employees
- ~32
- Development stage
- Phase 3
01
Overview
Pegargiminase (ADI‑PEG 20) is a novel biologic that deprives certain cancers of arginine and has been tested in over twenty clinical trials globally for various solid and hematologic tumors. It has received orphan drug status for several indications and is being evaluated both as monotherapy and in combination with chemotherapy or immuno-oncology agents. The company has established multiple regional licensing/distribution agreements to commercialize its lead asset internationally.
- Therapeutic areas
- OncologyHematology
- Modalities
- Protein therapeutics/biologics (notably pegylated enzymes such as Pegargiminase/ADI‑PEG 20)Small molecules (in early research programs)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Er-Kim Pharmaceuticals – exclusive distribution agreement for Pegargiminase across EMEA marketsTabuk Pharmaceutical Manufacturing Company – exclusive licensing agreement for Saudi Arabia & GCC regionMD Anderson Cancer Center – strategic collaboration on immunotherapy platform and biomarker studies
Beyond the preview
Go deeper on Polaris Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Polaris Pharmaceuticals.